Td Asset Management Inc Denali Therapeutics Inc. Transaction History

Td Asset Management Inc

$107 Billion
Q3 2024

A detailed history of Td Asset Management Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 244,552 shares of DNLI stock, worth $5.91 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

244,552

Previous 179,152 36.51%

Holding current value

$5.91 Million

Previous $4.16 Million 71.27%

% of portfolio

0.01%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$20.96 - $31.05 $1.37 Million - $2.03 Million	65,400 Added 36.51%	244,552 $7.12 Million
Q2 2024 Aug 02, 2024	BUY	$14.96 - $23.22 $116,179 - $180,326	7,766 Added 4.53%	179,152 $4.16 Million
Q1 2024 May 08, 2024	BUY	$15.83 - $23.35 $1.27 Million - $1.88 Million	80,342 Added 88.25%	171,386 $3.52 Million
Q4 2023 Feb 12, 2024	SELL	$16.2 - $23.18 $712,087 - $1.02 Million	-43,956 Reduced 32.56%	91,044 $1.95 Million
Q3 2023 Oct 27, 2023	BUY	$20.63 - $30.17 $1.04 Million - $1.53 Million	50,578 Added 59.91%	135,000 $2.79 Million
Q2 2023 Aug 09, 2023	SELL	$23.37 - $32.96 $91,143 - $128,544	-3,900 Reduced 4.42%	84,422 $2.49 Million
Q1 2023 May 10, 2023	SELL	$21.91 - $32.67 $238,534 - $355,678	-10,887 Reduced 10.97%	88,322 $2.03 Million
Q4 2022 Feb 06, 2023	BUY	$26.28 - $33.92 $133,660 - $172,517	5,086 Added 5.4%	99,209 $2.76 Million
Q3 2022 Nov 07, 2022	SELL	$25.97 - $38.53 $703,787 - $1.04 Million	-27,100 Reduced 22.36%	94,123 $2.76 Million
Q2 2022 Aug 04, 2022	SELL	$20.88 - $35.19 $246,676 - $415,734	-11,814 Reduced 8.88%	121,223 $3.57 Million
Q1 2022 May 10, 2022	BUY	$29.0 - $47.27 $310,300 - $505,789	10,700 Added 8.75%	133,037 $4.28 Million
Q4 2021 Feb 10, 2022	SELL	$42.59 - $55.02 $191,655 - $247,590	-4,500 Reduced 3.55%	122,337 $5.46 Million
Q2 2021 Aug 11, 2021	SELL	$50.3 - $78.44 $704,200 - $1.1 Million	-14,000 Reduced 9.94%	126,837 $6.47 Million
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $377,299 - $571,769	7,013 Added 5.24%	140,837 $8.04 Million
Q4 2020 Feb 16, 2021	BUY	$36.89 - $93.56 $1.29 Million - $3.26 Million	34,880 Added 35.25%	133,824 $11.2 Million
Q3 2020 Nov 10, 2020	BUY	$23.13 - $38.84 $956,124 - $1.61 Million	41,337 Added 71.76%	98,944 $3.55 Million
Q2 2020 Aug 13, 2020	BUY	$16.01 - $28.82 $398,649 - $717,618	24,900 Added 76.13%	57,607 $1.39 Million
Q1 2020 May 15, 2020	BUY	$14.2 - $27.98 $123,639 - $243,621	8,707 Added 36.28%	32,707 $573,000
Q3 2019 Nov 07, 2019	SELL	$15.32 - $21.92 $7,660 - $10,960	-500 Reduced 2.04%	24,000 $368,000
Q2 2019 Aug 01, 2019	BUY	$18.5 - $28.14 $20,350 - $30,954	1,100 Added 4.7%	24,500 $509,000
Q1 2019 May 08, 2019	BUY	$17.99 - $24.65 $8,995 - $12,325	500 Added 2.18%	23,400 $543,000
Q4 2018 Feb 01, 2019	BUY	$13.88 - $21.75 $6,940 - $10,875	500 Added 2.23%	22,900 $473,000
Q3 2018 Nov 01, 2018	BUY	$12.46 - $21.74 $74,760 - $130,439	6,000 Added 36.59%	22,400 $487,000
Q1 2018 May 11, 2018	BUY	$15.36 - $24.8 $251,904 - $406,720	16,400 New	16,400 $323,000

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.24B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account

Td Asset Management Inc Denali Therapeutics Inc. Transaction History